On 25-27 October, the EAU Section of Urological Research is convening in Strasbourg to provide Europe’s researchers a cutting edge overview of topics including prostate cancer, testicular cancer and the role of stem cell pathways in urothelial cancer. The meeting also showcases ESUR’s international ties, with speakers and sessions from different European bodies involved in prostate cancer research.
Abstract submission closes 15 June, and registration is possible at a reduced rate until 25 July. Prof. Zoran Culig (Innsbruck), ESUR Chairman, explains the nature of the Meeting’s scientific content.
“Firstly, we are focussing on getting a better understanding of dual androgen receptor action in prostate cancer. We would like to have more insight in androgen receptor regulation of proliferation and differentiation. There have been some recent novel developments, especially in the case of improved clinical therapies like Abiraterone and MDV3100. These are now in clinical use, following long periods of laboratory research. By examining these therapies, we can highlight the problems of resistance to therapy.”
A second topic at the meeting is testicular cancer. Because successful therapy is possible, this is a success story for researchers. “Laboratory research contributed greatly to curing this particular form of cancer. Two speakers will discuss the current results in treatment, and it is always an interesting topic to motivate researchers to work on a cure for other forms of cancer.” A third major topic for presentation and discussion is the role of stem cell pathways in urothelial cancer.